Comparison of infliximab drug measurement across three commercially available ELISA kits

Pathology

Volumn 48, Issue 6, 2016, Pages 608-612

  Lee, Monique Wei Meng ^a   Connor, Susan ^a,b   Ng, Watson ^a   Toong, Catherine Mei Ling ^a,b  

^a LIVERPOOL HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

antibodies to infliximab; ATI; Infliximab; therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; CRYOGLOBULIN; DRUG ANTIBODY; ETANERCEPT; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; DIAGNOSTIC KIT;

ANTIBODY BLOOD LEVEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; ELISA KIT; FALSE POSITIVE RESULT; FEMALE; HUMAN; MALE; MEASUREMENT ACCURACY; BLOOD; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; PROCEDURES; STANDARDS;

ANTIRHEUMATIC AGENTS; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLIXIMAB; REAGENT KITS, DIAGNOSTIC;

EID: 84994165187     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1016/j.pathol.2016.07.001     Document Type: Article

References (10)

1. 1 van Schie, K.A., Hart, M.H., de Groot, E.R., et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74 (2015), 311–314.
2. 2 Vande Casteele, N., Feagan, B.G., Gils, A., et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep, 16, 2014, 378.
3. 3 Seow, C.H., Newman, A., Irwin, S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59 (2010), 49–54.
4. 4 Adedokun, O.J., Sandborn, W.J., Feagan, B.G., et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 147 (2014), 1296–1307.
5. 5 Velayos, F.S., Kahn, J.G., Sandborn, W.J., et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 11 (2013), 654–666.
6. 6 Steenholdt, C., Brynskov, J., Thomsen, O.O., et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. Dig Dis Sci 60 (2015), 2762–2770.
7. 7 Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
8. 8 Vande Casteele, N., Khanna, R., Levesque, B.G., et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 64 (2015), 1539–1545.
9. 9 Willrich, M.A., Murray, D.L., Barnidge, D.R., et al. Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. Int Immunopharmacol 28 (2015), 513–520.
10. 10 Wang, S.L., Ohrmund, L., Hauenstein, S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 382 (2012), 177–188.